Benzinga | Nov 6, 2020 09:19AM EST

Roth Capital Maintains Buy on Global Blood Therapeutics, Lowers Price Target to $128

Roth Capital maintains Global Blood Therapeutics (NASDAQ:GBT) with a Buy and lowers the price target from $131 to $128.